{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T15:35:21Z","timestamp":1726760121839},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s00228-014-1776-9","type":"journal-article","created":{"date-parts":[[2014,11,3]],"date-time":"2014-11-03T04:22:26Z","timestamp":1414988546000},"page":"117-124","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relatives"],"prefix":"10.1007","volume":"71","author":[{"given":"Karin","family":"Hedenmalm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arzu Gunes","family":"Granberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marja-Liisa","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,1]]},"reference":[{"issue":"13","key":"1776_CR1","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","volume":"289","author":"PD Thompson","year":"2003","unstructured":"Thompson PD, Clarkson P, Karas RH (2003) Statin-associated myopathy. JAMA 289(13):1681\u20131690","journal-title":"JAMA"},{"issue":"6","key":"1776_CR2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.amjmed.2003.10.033","volume":"116","author":"RS Rosenson","year":"2004","unstructured":"Rosenson RS (2004) Current overview of statin-induced myopathy. Am J Med 116(6):408\u2013416","journal-title":"Am J Med"},{"key":"1776_CR3","doi-asserted-by":"crossref","unstructured":"(2003) How a statin might destroy a drug company. Lancet 361(9360):793","DOI":"10.1016\/S0140-6736(03)12723-7"},{"issue":"3","key":"1776_CR4","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jad.2011.09.042","volume":"136","author":"G Joshi","year":"2012","unstructured":"Joshi G, Petty C, Wozniak J, Faraone SV, Doyle R, Georgiopoulos A et al (2012) A prospective open-label trial of quetiapine monotherapy in preschool and school age children with bipolar spectrum disorder. J Affect Disord 136(3):1143\u20131153","journal-title":"J Affect Disord"},{"issue":"3","key":"1776_CR5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/pds.1895","volume":"19","author":"K Hedenmalm","year":"2010","unstructured":"Hedenmalm K, Alvan G, Ohagen P, Dahl ML (2010) Muscle toxicity with statins. Pharmacoepidemiol Drug Saf 19(3):223\u2013231","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"1776_CR6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00002018-200225090-00004","volume":"25","author":"M Evans","year":"2002","unstructured":"Evans M, Rees A (2002) Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 25(9):649\u2013663","journal-title":"Drug Saf"},{"issue":"3","key":"1776_CR7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00002018-200023030-00003","volume":"23","author":"JA Farmer","year":"2000","unstructured":"Farmer JA, Torre-Amione G (2000) Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf 23(3):197\u2013213","journal-title":"Drug Saf"},{"issue":"3","key":"1776_CR8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1254\/jphs.93.279","volume":"93","author":"R Inoue","year":"2003","unstructured":"Inoue R, Tanabe M, Kono K, Maruyama K, Ikemoto T, Endo M (2003) Ca2+-releasing effect of cerivastatin on the sarcoplasmic reticulum of mouse and rat skeletal muscle fibers. J Pharmacol Sci 93(3):279\u2013288","journal-title":"J Pharmacol Sci"},{"issue":"7","key":"1776_CR9","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/00003643-200407000-00013","volume":"21","author":"R Krivosic-Horber","year":"2004","unstructured":"Krivosic-Horber R, Depret T, Wagner JM, Maurage CA (2004) Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment. Eur J Anaesthesiol 21(7):572\u2013574","journal-title":"Eur J Anaesthesiol"},{"issue":"2","key":"1776_CR10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/art.11013","volume":"49","author":"S Guis","year":"2003","unstructured":"Guis S, Bendahan D, Kozak-Ribbens G, Figarella-Branger D, Mattei JP, Pellissier JF et al (2003) Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility. Arthritis Rheum 49(2):237\u2013238","journal-title":"Arthritis Rheum"},{"issue":"1\u20132","key":"1776_CR11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ymgme.2011.07.001","volume":"104","author":"GD Vladutiu","year":"2011","unstructured":"Vladutiu GD, Isackson PJ, Kaufman K, Harley JB, Cobb B, Christopher-Stine L et al (2011) Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies. Mol Genet Metab 104(1\u20132):167\u2013173","journal-title":"Mol Genet Metab"},{"issue":"9134","key":"1776_CR12","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0140-6736(98)03078-5","volume":"352","author":"M Denborough","year":"1998","unstructured":"Denborough M (1998) Malignant hyperthermia. Lancet 352(9134):1131\u20131136","journal-title":"Lancet"},{"issue":"4","key":"1776_CR13","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/bja\/88.4.508","volume":"88","author":"M Davis","year":"2002","unstructured":"Davis M, Brown R, Dickson A, Horton H, James D, Laing N et al (2002) Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees. Br J Anaesth 88(4):508\u2013515","journal-title":"Br J Anaesth"},{"issue":"1","key":"1776_CR14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/bja\/85.1.118","volume":"85","author":"PM Hopkins","year":"2000","unstructured":"Hopkins PM (2000) Malignant hyperthermia: advances in clinical management and diagnosis. Br J Anaesth 85(1):118\u2013128","journal-title":"Br J Anaesth"},{"issue":"5","key":"1776_CR15","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/bja\/87.5.794","volume":"87","author":"F Wappler","year":"2001","unstructured":"Wappler F, Fiege M, Schulte am Esch J (2001) Pathophysiological role of the serotonin system in malignant hyperthermia. Br J Anaesth 87(5):794\u2013798","journal-title":"Br J Anaesth"},{"issue":"11","key":"1776_CR16","doi-asserted-by":"crossref","first-page":"a003996","DOI":"10.1101\/cshperspect.a003996","volume":"2","author":"JT Lanner","year":"2010","unstructured":"Lanner JT, Georgiou DK, Joshi AD, Hamilton SL (2010) Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb Perspect Biol 2(11):a003996","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"5","key":"1776_CR17","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/ALN.0b013e3182320068","volume":"115","author":"L Groom","year":"2011","unstructured":"Groom L, Muldoon SM, Tang ZZ, Brandom BW, Bayarsaikhan M, Bina S et al (2011) Identical de novo mutation in the type 1 ryanodine receptor gene associated with fatal, stress-induced malignant hyperthermia in two unrelated families. Anesthesiology 115(5):938\u2013945","journal-title":"Anesthesiology"},{"key":"1776_CR18","doi-asserted-by":"crossref","unstructured":"Rosenberg H, Rueffert H (2011) Clinical utility gene card for: malignant hyperthermia. Eur J Human Genet 19(6)","DOI":"10.1038\/ejhg.2010.248"},{"issue":"2","key":"1776_CR19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/bja\/86.2.283","volume":"86","author":"A Urwyler","year":"2001","unstructured":"Urwyler A, Deufel T, McCarthy T, West S (2001) Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 86(2):283\u2013287","journal-title":"Br J Anaesth"},{"issue":"9","key":"1776_CR20","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/j.1365-2044.2012.07226.x","volume":"67","author":"T Russell","year":"2012","unstructured":"Russell T, Riazi S, Kraeva N, Steel AC, Hawryluck LA (2012) Ecstacy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene. Anaesthesia 67(9):1021\u20131024","journal-title":"Anaesthesia"},{"issue":"1\u20133","key":"1776_CR21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.forsciint.2009.10.014","volume":"194","author":"T Sato","year":"2010","unstructured":"Sato T, Nishio H, Iwata M, Kentotsuboi, Tamura A, Miyazaki T et al (2010) Postmortem molecular screening for mutations in ryanodine receptor type 1 (RYR1) gene in psychiatric patients suspected of having died of neuroleptic malignant syndrome. Forensic Sci Int 194(1\u20133):77\u201379","journal-title":"Forensic Sci Int"},{"issue":"2","key":"1776_CR22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","volume":"34","author":"GD Vladutiu","year":"2006","unstructured":"Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC et al (2006) Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 34(2):153\u2013162","journal-title":"Muscle Nerve"},{"issue":"3B","key":"1776_CR23","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1590\/S0004-282X2007000500020","volume":"65","author":"PJ Lorenzoni","year":"2007","unstructured":"Lorenzoni PJ, Silvado CE, Scola RH, Luvizotto M, Werneck LC (2007) McArdle disease with rhabdomyolysis induced by rosuvastatin: case report. Arq Neuropsiquiatr 65(3B):834\u2013837","journal-title":"Arq Neuropsiquiatr"},{"issue":"Pt 5","key":"1776_CR24","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1258\/000456303322326542","volume":"40","author":"JH Barth","year":"2003","unstructured":"Barth JH, Brownjohn AM, Jamieson DR (2003) The case of stainless statins. Ann Clin Biochem 40(Pt 5):576\u2013577","journal-title":"Ann Clin Biochem"},{"issue":"Pt 4","key":"1776_CR25","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1258\/0004563041201554","volume":"41","author":"C Livingstone","year":"2004","unstructured":"Livingstone C, Al Riyami S, Wilkins P, Ferns GA (2004) McArdle\u2019s disease diagnosed following statin-induced myositis. Ann Clin Biochem 41(Pt 4):338\u2013340","journal-title":"Ann Clin Biochem"},{"issue":"2","key":"1776_CR26","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2796.2005.01515.x","volume":"258","author":"NC Voermans","year":"2005","unstructured":"Voermans NC, Lammens M, Wevers RA, Hermus AR, van Engelen BG (2005) Statin-disclosed acid maltase deficiency. J Intern Med 258(2):196\u2013197","journal-title":"J Intern Med"},{"issue":"1","key":"1776_CR27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2013.09.011","volume":"24","author":"M Needham","year":"2014","unstructured":"Needham M, Mastaglia FL (2014) Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord NMD 24(1):4\u201315","journal-title":"Neuromuscul Disord NMD"},{"issue":"8","key":"1776_CR28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"E Link","year":"2008","unstructured":"Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F et al (2008) SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study. N Engl J Med 359(8):789\u2013799","journal-title":"N Engl J Med"},{"issue":"3","key":"1776_CR29","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1056\/NEJMc081975","volume":"360","author":"GD Vladutiu","year":"2009","unstructured":"Vladutiu GD, Isackson PJ (2009) SLCO1B1 variants and statin-induced myopathy. N Engl J Med 360(3):304","journal-title":"N Engl J Med"},{"key":"1776_CR30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/tpj.2010.92","volume":"12","author":"LR Brunham","year":"2012","unstructured":"Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK et al (2012) Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 12:233\u2013237","journal-title":"Pharmacogenomics J"},{"issue":"12","key":"1776_CR31","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","volume":"16","author":"MK Pasanen","year":"2006","unstructured":"Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M (2006) SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16(12):873\u2013879","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"1776_CR32","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","volume":"82","author":"MK Pasanen","year":"2007","unstructured":"Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M (2007) Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82(6):726\u2013733","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1776-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-014-1776-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1776-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T08:49:11Z","timestamp":1558687751000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-014-1776-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["1776"],"URL":"https:\/\/doi.org\/10.1007\/s00228-014-1776-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,1]]}}}